

References

I-58

1. Doerfler P, Nayak S, Corti M, et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. *Mol Ther Methods Clin Dev.* 2016;3:15053.
2. Micromedex DrugDex Compendium®. 2022. Alglucosidase alfa.
3. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Alglucosidase alfa.
4. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
5. Van der Meijden JC, Kruijshaar ME, Harlaar L, et al. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. *J Inherit Metab Dis.* 2018; 41(6):1205-14.
6. Byrne BJ, Fuller DD, Smith BK, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. *Ann Transl Med.* 2019;(13):290-302.
7. Parini R, De Lorenzo P, Dardis A, et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. *Orphanet J Rare Dis.* 2018; 13(1):32.
8. Confalonieri M, Vitacca M, Scala R, et al. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. *Orphanet J Rare Dis.* 2019;14(1):62.
9. Alglucosidase alfa (Lumizyme) for injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Revised 02/2021.
10. Avalglucosidase alfa-ngpt (Nexviazyme) for injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Issued 08/2021.
11. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Avalglucosidase alfa.
12. Micromedex DrugDex Compendium®. 2022. Avalglucosidase alfa-ngpt.
13. Avalglucosidase Alfa-ngpt In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 30, 2021.
14. Avalglucosidase alfa-ngpt. Lexi-Drugs. Hudson, OH: Lexicomp, 2022.
15. Pena LDM, Barohn RJ, Byrne BJ, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label,

- multicenter, multinational, ascending dose study. *Neuromuscul Disord*. 2019;29(3):167-186.
16. Alglucosidase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
 17. Cao JD, Wiedemann A, Quinaux T, et al. 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. *Mol Genet Metab Rep*. 2016;42-45.
 18. Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. *Appl Clin Genet*. 2016;9:67–74.
 19. Finnigan N, Roberts J, Mercer J, et al. Home infusion with elosulfase alpha (Vimizim) in a UK pediatric setting. *Mol Genet Metab Rep*. 2017;15–18.
 20. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. 2016.
 21. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
 22. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
 23. Micromedex DrugDex Compendium®. 2022. Elosulfase Alfa.
 24. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Elosulfase alfa.
 25. Elosulfase alfa (Vimizim™) for intravenous administration [package insert]. BioMarin Pharmaceuticals Inc. Novato, CA. Revised 12/2019.
 26. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167(1):11–25.
 27. Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS IVA: Systematic evidence- and consensus-based guidance. *Orphanet J Rare Dis*. 2019;14(137).
 28. Hendriksz CJ, Parini R, Al Sayed MD, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. *Mol Genet Metab*. 2016;119(1-2):131-43.
 29. Harmatz PR, Mengel KE, Giugliani R et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. *Mol Genet Metab Rep*. 2015;114(2):186-94.
 30. Ficicioglu C, Matalon DR, Luongo N, et al. Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study. *Orphanet J Rare Dis*. 2020;15(1):336-46.
 31. Barak S, Anikster Y, Sarouk I, Stern E, et al. Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings. 2020;10(2):108-19
 32. Elosulfase alfa. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.

33. Elosulfase alfa In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 2, 2016
34. Erazo-Narváez AF, Muñoz-Vidal JM, Rodríguez-Vélez GH, Acosta-Aragón MA. Clinical outcomes in elderly patients with Morquio a syndrome receiving enzyme replacement therapy - experience in a Colombian center. *Mol Genet Metab Rep.* 2020 2;25:1-8.
35. Naglazyme® (galsulfase), injection, for intravenous use [package insert]. BioMarin Pharmaceutical Inc. Novato, CA. Revised 12/2019.
36. Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. *Mol Genet Metab.* 2017;13:69-75.
37. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Galsulfase.
38. American Society of Health-System Pharmacists. ASHP guidelines on home infusion pharmacy services. *Am J Health-Syst Pharm.* 2014;71:325–41.
39. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
40. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthc(Amst).* 2017;5(1-2):68-80.
41. American Society of Health-System Pharmacists. ASHP guidelines on evaluating and using home or alternate-site infusion service providers. *Am J Health-Syst Pharm.* 2016;73:922–6.
42. Quartel A, Harmatz PR, Lampe C, et al. Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) 15-year follow-up from the survey study. *J Inborn Errors Metab Screen.* 2018;6:1-6.
43. Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS VI: systematic evidence-and consensus-based guidance. *Orphanet J Rare Dis.* 2019;14(1):118.
44. Garcia P, Phillips D, Johnson J, et al. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy. *Mol Genet Metab.* 2021;133(1):100-108.
45. Micromedex DrugDex Compendium®. 2022. Galsulfase.
46. Galsulfase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 1, 2006.
47. Eleprase® (Idursulfase) injection, for intravenous use [package insert]. Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA. Revised 9/2021.
48. Pano A, Barbier A, Bielefeld B, et al. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). *Orphanet J Rare Dis.* 2015;10:

49. Muenzer J, Hendriksz C, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. *Genet in Medicine*. 2015;36.
50. Sestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. *Res Rep Endocr Disord*. 2015;5:79-90.
51. Guffon N, Heron B, Chabrol B, et al. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: A retrospective observational study. *Orphanet J Rare Dis*. 2015;10:43.
52. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
53. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
54. Micromedex DrugDex Compendium®. 2022. Idursulfase.
55. Idursulfase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated September 1, 2010.
56. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Idursulfase.
57. Muenzer J, Jones SA, Tylki-Szymańska A, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. *Orphanet J Rare Dis*. 2017. 12(1):82.
58. Bradley L. A., Haddow H. R., & Palomaki G. E. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review. *Genet Medicine*. 19(11), 1187-1201.
59. Erwin AL. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. *Ther Adv Gastroenterol*. 2017;553-562.
60. Micromedex DrugDex Compendium®. 2022. Sebelipase alfa.
61. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Sebelipase alfa.
62. Kanuma (sebelipase alfa) Intravenous Infusion [package insert]. Alexion Pharmaceuticals Inc. New Haven, CT. Revised 12/2015.
63. Jones SA, Rojas-Caro S, Quinn AG, Friedman M, Marulkar S, Ezgu F, et al. Survival in infants treated with sebelipase alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. *Orphanet J Rare Dis*. 2017; 12(25):1-12.
64. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
65. Jones SA, Valayannopoulos V, Schneider E, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. *Genet Med*. 2016 18(5), 452-458.

66. Patterson C, So S, DeAngelis M, Ghent E, Southmayd D, and Carpenter C. Physical activity experiences in children post–liver transplant: Developing a foundation for rehabilitation interventions. *Pediatr Transplant*. 22(4), e13179.
67. Sebelipase Alfa In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 22, 2017.
68. Sebelipase Alfa. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
69. Potter JE, Petts G, Ghosh A. *et al.* Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease. *Orphanet J Rare Dis*. 2021;16(235): 1-14.
70. Vijay S, Brassier A, Ghosh A. *et al.* Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies. *Orphanet J Rare Dis*. 2021;16(13): 1-16.
71. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc.. Vestronidase alfa.
72. Mepsevii™ (vestronidase alfa-vjvk), for intravenous infusion [package insert]. Ultragenyx Pharmaceutical, Inc. Novato, CA. Revised 12/2020.
73. Montano A, Lock-Hock N, Steiner R, et al. Clinical course of sly syndrome (Mucopolysaccharidosis Type VII). *J Med Genet*. 2016;53(6):403-418.
74. Fox J, Volpe L, Bullaro J, et al. Treatment with investigational rhGUS enzyme replacement therapy in an advance stage MPS VII patient. *Mol Genet Metab*. 2015;114(2):203-208.
75. Qi Y, McKeever K, Taylor J, et al. Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials. *Clin Pharmacokinet*. 2019;58(5):673-83.
76. Harmatz P, Whitley CB, Wang RY, et al. A novel bind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. *Mol Genet Meta* 2018;123(4):488-94.
77. Morrison A, Oussoren E, Friedel T, et al. Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII—a European caregiver survey. *Orphanet J Rare Dis*. 2019;14 (1):254.
78. McCafferty EH, Scott LJ. Vestronidase alfa: a review in mucopolysaccharidosis VII. 2019;11;33(2):233-240.
79. Wang R, da Silva Franco JF, Lopez-Valdez J, et al. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. *Mol Genet Metab*. 2020;129(3):219-227.

80. Vestronidase alfa-vjvk In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 20, 2019.
81. Micromedex DrugDex Compendium®. 2022. Vestronidase Alfa-vjvk.
82. Aldurazyme® (laronidase) [package insert]. BioMarin Pharmaceutical, Inc.; Novarto, CA, Revised 12/2019.
83. Micromedex DrugDex Compendium®. 2022. Laronidase.
84. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Laronidase.
85. Dornelles A, Artigas O, Anjos da Silva A, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. *PLoS ONE*. 2017; 12(8): 1-18.
86. Laronidase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 1, 2003.
87. Jameson E, Jones S, Remington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. *Cochrane Database of Systematic Reviews*. 2019;6:1-24.
88. Fabrazyme® (agalsidase beta) for injection, for intravenous use. [package insert]. Genzyme Corp. Cambridge, MA: Revised 12/2018.
89. Micromedex DrugDex Compendium®. 2022. Agalsidase beta.
90. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Agalsidase beta.
91. Ortiz A, Kanters S, Hamed A, et al. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. *Clin Kidney J*. 2020;1-11.
92. Agalsidase beta In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 1, 2006.